Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 22.36M | 22.34M | 2.99M | 3.09M | 2.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.36M | 22.34M | 2.99M | 3.09M | 2.87M |
| Cost of Revenue | 17.15M | 23.10M | 24.78M | 25.70M | 26.48M |
| Gross Profit | 5.21M | -756.00K | -21.79M | -22.61M | -23.62M |
| SG&A Expenses | 5.86M | 6.44M | 6.81M | 7.16M | 7.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.02M | 29.54M | 31.59M | 32.86M | 33.99M |
| Operating Income | -656.00K | -7.20M | -28.61M | -29.77M | -31.13M |
| Income Before Tax | -1.14M | -9.30M | -29.42M | -30.37M | -32.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.14 | -9.30 | -29.42 | -30.37 | -32.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.14M | -9.30M | -29.42M | -30.37M | -32.79M |
| EBIT | -656.00K | -7.20M | -28.61M | -29.77M | -31.13M |
| EBITDA | -347.00K | -6.82M | -28.16M | -29.28M | -30.58M |
| EPS Basic | -0.18 | -0.64 | -1.43 | -1.65 | -1.96 |
| Normalized Basic EPS | -0.10 | -0.35 | -0.86 | -1.00 | -1.18 |
| EPS Diluted | -0.19 | -0.65 | -1.44 | -1.65 | -1.97 |
| Normalized Diluted EPS | -0.11 | -0.35 | -0.86 | -1.00 | -1.18 |
| Average Basic Shares Outstanding | 125.95M | 106.22M | 87.82M | 75.11M | 67.60M |
| Average Diluted Shares Outstanding | 126.45M | 106.72M | 87.82M | 75.11M | 67.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |